{
  "directed": true,
  "graph": {
    "annotation_list": {
      "Custom_Disease": [
        "COVID-19"
      ],
      "PublicationStatus": [
        "Published"
      ],
      "PublicationType": [
        "Commentary"
      ],
      "Section": [
        "Abstract",
        "Full Text"
      ],
      "Timeline": [
        "28 days"
      ]
    },
    "annotation_pattern": {},
    "annotation_url": {
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20190128.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20190128.belanno",
      "Species": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Abish K",
      "contact": "abish@causalitybiomodels.com",
      "copyright": "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved",
      "description": "COVID Knowledge Curation project",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "name": "32129518.bel",
      "version": "2.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
      "COVID": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-covid19/ncbi-covid19-20200326.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
      "GO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
      "HGNC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
      "MESH": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns",
      "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20190128.belns",
      "TAX": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
    },
    "path": "32129518.bel",
    "pybel_version": "0.14.6"
  },
  "links": [
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections.",
      "key": "23e4a5a486fd443853f2b84bb94a70b7",
      "line": 53,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 3,
      "target": 22
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Hypertension": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "The AT1R antagonists losartan and olmesartan, commonly applied for reducing blood pressure in hypertensive patients, were shown to increase cardiac ACE2 expression about three-fold following chronic treatment (28 days) after myocardial infarction induced by coronary artery ligation of rats (Ishiyama et al., 2004).",
      "key": "1dd1ae0b2b928576e0b2a5cb19b73e0f",
      "line": 93,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 3,
      "target": 22
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections.",
      "key": "5d65234bb453b95ec048fb1d90ff407d",
      "line": 54,
      "relation": "isA",
      "source": 3,
      "target": 2
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Heart": true
        },
        "MeSHDisease": {
          "Myocardial Infarction": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "10116": true
        },
        "Timeline": {
          "28 days": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "The AT1R antagonists losartan and olmesartan, commonly applied for reducing blood pressure in hypertensive patients, were shown to increase cardiac ACE2 expression about three-fold following chronic treatment (28 days) after myocardial infarction induced by coronary artery ligation of rats (Ishiyama et al., 2004).",
      "key": "b7d3d58afc97e9a1d80f1c8658a1b7ec",
      "line": 101,
      "relation": "increases",
      "source": 3,
      "target": 24
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Kidney": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan was also shown to upregulate renal ACE2 expression in chronically treated rats (Klimas et al., 2015). In agreement with these observations, higher urinary ACE2 levels were observed in hypertensive patients treated with the AT1R antagonist olmesartan (Furuhashi et al., 2015).",
      "key": "1527f6da1ab9b26dac66006a8c649a4f",
      "line": 112,
      "relation": "increases",
      "source": 3,
      "target": 24
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "f68aac99c72df32febb8b7f256e7c049",
      "line": 163,
      "relation": "decreases",
      "source": 3,
      "target": 30
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "e386bfa0bc3790ca203d6e9d8faae005",
      "line": 164,
      "relation": "decreases",
      "source": 3,
      "target": 28
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections.",
      "key": "fc1e6152b69cf27a2d8b0e6367f9b8c6",
      "line": 55,
      "relation": "positiveCorrelation",
      "source": 22,
      "subject": {
        "modifier": "Activity"
      },
      "target": 27
    },
    {
      "key": "2eddd69822628dd852f7fbede4a5e6e5",
      "relation": "partOf",
      "source": 22,
      "target": 14
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "ACE cleaves angiotensin I to generate angiotensin II, the peptide which binds to and activates AT1R to constrict blood vessels, thereby elevating blood pressure.",
      "key": "d5b39f4525d2db0b0156a441c1514458",
      "line": 79,
      "relation": "increases",
      "source": 22,
      "subject": {
        "modifier": "Activity"
      },
      "target": 10
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Taken together, these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans.",
      "key": "9e0d52bc8b1d75ccbda0f492afe7c2b9",
      "line": 124,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 22,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This in turn contributes to lung injury, as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability, thereby mediating increased lung pathology (Imai et al., 2005; Kuba et al., 2005).",
      "key": "2753f0d2b143da57ae59dcf105baad46",
      "line": 142,
      "relation": "decreases",
      "source": 22,
      "subject": {
        "modifier": "Activity"
      },
      "target": 9
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A recent hypothesis suggested that angiotensin receptor 1 (AT1R) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia (Sun, Yang, Sun, & Su, 2020).",
      "key": "57b240c3a08bdc57bb4cba59e9dab270",
      "line": 65,
      "relation": "decreases",
      "source": 2,
      "target": 31
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Therefore, higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers, while seemingly paradoxical, may protect them against acute lung injury rather than putting them at higher risk to develop SARS.",
      "key": "13853fb6bed45c28b4b75b6a6c5e8db9",
      "line": 147,
      "relation": "increases",
      "source": 2,
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "If the latter percentage would be found to be significantly smaller, this would support the notion that AT1R antagonists confer protection from severe symptoms among SARS-CoV-2 infected individuals.",
      "key": "8762916a6e36672c8c46059e0695087f",
      "line": 171,
      "relation": "negativeCorrelation",
      "source": 2,
      "target": 27
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections.",
      "key": "60ba05fea3b186bd60f65c7c7127ba62",
      "line": 55,
      "object": {
        "modifier": "Activity"
      },
      "relation": "positiveCorrelation",
      "source": 27,
      "target": 22
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A recent hypothesis suggested that angiotensin receptor 1 (AT1R) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia (Sun, Yang, Sun, & Su, 2020).",
      "key": "3a1ae930f14bf3c3d042f551d13e80d4",
      "line": 66,
      "relation": "association",
      "source": 27,
      "target": 31
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "f4d252e178798b019e7b436c4615b7cc",
      "line": 153,
      "relation": "positiveCorrelation",
      "source": 27,
      "target": 1
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "If the latter percentage would be found to be significantly smaller, this would support the notion that AT1R antagonists confer protection from severe symptoms among SARS-CoV-2 infected individuals.",
      "key": "c7744d515e52e7204ab584a5fbfacb6a",
      "line": 171,
      "relation": "negativeCorrelation",
      "source": 27,
      "target": 2
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002–2003 SARS epidemic.",
      "key": "73d7acf0daf3d106e8cd7f9e72053798",
      "line": 59,
      "relation": "increases",
      "source": 15,
      "target": 27
    },
    {
      "key": "9b5e6ebdb508b622c266b4b986bd47ee",
      "relation": "partOf",
      "source": 7,
      "target": 15
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "53488c2cd561c32258df15063ba1d645",
      "line": 71,
      "relation": "association",
      "source": 7,
      "target": 19
    },
    {
      "key": "52cb6d8fcf894bbfe8497cecebc5b0d1",
      "relation": "partOf",
      "source": 21,
      "target": 15
    },
    {
      "key": "44a4b634ca32139aded9fc5a719f4996",
      "relation": "partOf",
      "source": 21,
      "target": 16
    },
    {
      "key": "1db03b2523b3b2cd2b465edf9382bc2a",
      "relation": "partOf",
      "source": 21,
      "target": 17
    },
    {
      "key": "91585dfb07b68567219a2cb720e5cf5e",
      "relation": "partOf",
      "source": 21,
      "target": 18
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "ad110365f366f90b41024b2620c79b88",
      "line": 84,
      "relation": "decreases",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2, its cellular binding site, leads to ACE2 downregulation, which in turn results in excessive production of angiotensin by the related enzyme ACE, while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1–7.",
      "key": "7909a07fa42e84c151a0c4c2d0445170",
      "line": 135,
      "relation": "decreases",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "546ab2ad6751fe0cbb9a2070297033f6",
      "line": 156,
      "relation": "decreases",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "0462f174b8fd0413d07f9d07b039e81c",
      "line": 85,
      "relation": "increases",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 6
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "4d7a7de9b260fb5db3bfabbff60f63bf",
      "line": 158,
      "relation": "increases",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 6
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "4b3a4d9c7b740d3494c52ffef480f47d",
      "line": 88,
      "relation": "negativeCorrelation",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 13
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Taken together, these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans.",
      "key": "79cf90c6a15334da6eb7ed2d1a7019c5",
      "line": 124,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 22
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2, its cellular binding site, leads to ACE2 downregulation, which in turn results in excessive production of angiotensin by the related enzyme ACE, while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1–7.",
      "key": "a35fc021c017133818330b0e6612952e",
      "line": 136,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 20
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "041b0b277ac6ff03eb5af310496f4086",
      "line": 155,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 20
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Therefore, higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers, while seemingly paradoxical, may protect them against acute lung injury rather than putting them at higher risk to develop SARS.",
      "key": "2e494323695df7f104342ea7510216c1",
      "line": 148,
      "relation": "negativeCorrelation",
      "source": 21,
      "subject": {
        "modifier": "Activity"
      },
      "target": 32
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Abstract": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002–2003 SARS epidemic.",
      "key": "b50dcdc2c0bb2c13eac3399b0e14221f",
      "line": 60,
      "relation": "increases",
      "source": 16,
      "target": 29
    },
    {
      "key": "99fd5b71af427449b3c299ded846d810",
      "relation": "partOf",
      "source": 8,
      "target": 16
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "fe07151d3c75455901bde48757a8ad86",
      "line": 73,
      "relation": "association",
      "source": 8,
      "target": 26
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "A recent hypothesis suggested that angiotensin receptor 1 (AT1R) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia (Sun, Yang, Sun, & Su, 2020).",
      "key": "c7344f8596a3ea98532d538ec82ad369",
      "line": 66,
      "relation": "association",
      "source": 31,
      "target": 27
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "4f92bb84796fa45895c259ddb346dc99",
      "line": 70,
      "relation": "increases",
      "source": 17,
      "target": 27
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2, its cellular binding site, leads to ACE2 downregulation, which in turn results in excessive production of angiotensin by the related enzyme ACE, while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1–7.",
      "key": "57702ece76732a97a5f4830d6acd8363",
      "line": 134,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 17,
      "target": 21
    },
    {
      "key": "cc2d182e46a7afcbe8de0b32b4f87ed1",
      "relation": "partOf",
      "source": 19,
      "target": 17
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "f7a183e58d98a22d5991b104623fb605",
      "line": 71,
      "relation": "association",
      "source": 19,
      "target": 7
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "5f4b7fee9d74adc0ae36dd3d67273165",
      "line": 72,
      "relation": "increases",
      "source": 18,
      "target": 29
    },
    {
      "key": "e9a19617010334e4a7cd5c4ca2c08702",
      "relation": "partOf",
      "source": 26,
      "target": 18
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein (Lu et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), similarly to the coronavirus strain implicated in the 2002–2003 SARS epidemic (Dimitrov, 2003; Ge et al., 2013; Li et al., 2003; Prabakaran et al 2004; Turner, Hiscox, & Hooper, 2004).",
      "key": "dd713fe8bc77f13d0b7988d1f89ea28c",
      "line": 73,
      "relation": "association",
      "source": 26,
      "target": 8
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "ACE cleaves angiotensin I to generate angiotensin II, the peptide which binds to and activates AT1R to constrict blood vessels, thereby elevating blood pressure.",
      "key": "4f23e20f4f6ad024c6219c81a9073aea",
      "line": 77,
      "relation": "increases",
      "source": 20,
      "subject": {
        "effect": {
          "name": "cat",
          "namespace": "bel"
        },
        "modifier": "Activity"
      },
      "target": 33
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2, its cellular binding site, leads to ACE2 downregulation, which in turn results in excessive production of angiotensin by the related enzyme ACE, while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1–7.",
      "key": "3724ac7e567b3f88fcd5a24659478b5f",
      "line": 136,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 20,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "72bdb30404452721e1497737f1cce0af",
      "line": 155,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 20,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "038a53c1f7559657a5d5f087e50f049a",
      "line": 157,
      "relation": "increases",
      "source": 20,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "key": "b46c68f0101675cbf474fc5f62c27f66",
      "relation": "hasReactant",
      "source": 33,
      "target": 0
    },
    {
      "key": "cc899e488e5679d40c70fd677ca6d733",
      "relation": "hasProduct",
      "source": 33,
      "target": 1
    },
    {
      "key": "ea029bcd56961235a0dd0813c0012387",
      "relation": "partOf",
      "source": 1,
      "target": 14
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This in turn contributes to lung injury, as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability, thereby mediating increased lung pathology (Imai et al., 2005; Kuba et al., 2005).",
      "key": "b7efff1fb3ffa18d5b145b046a845f09",
      "line": 141,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 1,
      "target": 22
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "f800cd3c933882b893e8bae7de128acb",
      "line": 154,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 1,
      "target": 22
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "fb12c762683f2e35dcdea1dcc11185b5",
      "line": 153,
      "relation": "positiveCorrelation",
      "source": 1,
      "target": 27
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "ACE cleaves angiotensin I to generate angiotensin II, the peptide which binds to and activates AT1R to constrict blood vessels, thereby elevating blood pressure.",
      "key": "cefcae9b7adf0055f62716835b7e2c22",
      "line": 78,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 14,
      "target": 22
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "ACE cleaves angiotensin I to generate angiotensin II, the peptide which binds to and activates AT1R to constrict blood vessels, thereby elevating blood pressure.",
      "key": "ef162b0ac940e12dfc77cc58e79e5d8e",
      "line": 80,
      "relation": "increases",
      "source": 10,
      "target": 12
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "7a6e4e72ba82db502f3791aed4c9231c",
      "line": 86,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 6,
      "target": 23
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This may be accounted for by two complementary mechanisms: blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection, as well as upregulating ACE2, thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1–7.",
      "key": "e92645935894c858d64767e69d11a904",
      "line": 159,
      "relation": "increases",
      "source": 6,
      "target": 11
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "b7b629ed67a791121c00e93e12c929fb",
      "line": 87,
      "relation": "increases",
      "source": 23,
      "subject": {
        "modifier": "Activity"
      },
      "target": 11
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "By contract, ACE2 inactivates angiotensin II while generating angiotensin 1–7, a heptapeptide having a potent vasodilator function via activation of its Mas receptor (Santos et al., 2003), and thus serving as a negative regulator of the renin–angiotensin system.",
      "key": "70e5d97be1249c56bb5fecaedea119b8",
      "line": 88,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 13,
      "target": 21
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Hypertension": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "The AT1R antagonists losartan and olmesartan, commonly applied for reducing blood pressure in hypertensive patients, were shown to increase cardiac ACE2 expression about three-fold following chronic treatment (28 days) after myocardial infarction induced by coronary artery ligation of rats (Ishiyama et al., 2004).",
      "key": "1f7e07eb2d1985980ff439e1ddd56eda",
      "line": 94,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 4,
      "target": 22
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Heart": true
        },
        "MeSHDisease": {
          "Myocardial Infarction": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "10116": true
        },
        "Timeline": {
          "28 days": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "The AT1R antagonists losartan and olmesartan, commonly applied for reducing blood pressure in hypertensive patients, were shown to increase cardiac ACE2 expression about three-fold following chronic treatment (28 days) after myocardial infarction induced by coronary artery ligation of rats (Ishiyama et al., 2004).",
      "key": "b3c858befd807d4977ee442396b06273",
      "line": 102,
      "relation": "increases",
      "source": 4,
      "target": 24
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Urine": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan was also shown to upregulate renal ACE2 expression in chronically treated rats (Klimas et al., 2015). In agreement with these observations, higher urinary ACE2 levels were observed in hypertensive patients treated with the AT1R antagonist olmesartan (Furuhashi et al., 2015).",
      "key": "e845846bf9d87103b3fa837d2fdd262e",
      "line": 117,
      "relation": "increases",
      "source": 4,
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "a81d1a8d4b04a911416db08e74fee8e2",
      "line": 167,
      "relation": "decreases",
      "source": 4,
      "target": 30
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "21456f9fa52d13933189da594bdfdde6",
      "line": 168,
      "relation": "decreases",
      "source": 4,
      "target": 28
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Taken together, these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans.",
      "key": "7360a87a6b090ec8d78f7e136d4b755f",
      "line": 127,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 24,
      "subject": {
        "modifier": "Activity"
      },
      "target": 25
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Taken together, these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans.",
      "key": "d25083747f38b764d4ca00d9b91a6607",
      "line": 127,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 25,
      "subject": {
        "modifier": "Activity"
      },
      "target": 24
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This in turn contributes to lung injury, as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability, thereby mediating increased lung pathology (Imai et al., 2005; Kuba et al., 2005).",
      "key": "c4df8d0df70da9fd024df068fcbe6465",
      "line": 143,
      "relation": "negativeCorrelation",
      "source": 9,
      "target": 32
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "This in turn contributes to lung injury, as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability, thereby mediating increased lung pathology (Imai et al., 2005; Kuba et al., 2005).",
      "key": "488ed0f86c1293878973f5c1db59be18",
      "line": 143,
      "relation": "negativeCorrelation",
      "source": 32,
      "target": 9
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Therefore, higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers, while seemingly paradoxical, may protect them against acute lung injury rather than putting them at higher risk to develop SARS.",
      "key": "066905234895f82f1117719771ca2baf",
      "line": 148,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 32,
      "target": 21
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "9662de0065dfade927ba0508964a9d25",
      "line": 165,
      "relation": "decreases",
      "source": 5,
      "target": 30
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commentary": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Gurwitz D"
        ],
        "date": "2020-03-04",
        "db": "PubMed",
        "db_id": "32129518",
        "db_name": "Drug development research",
        "first": "Gurwitz D",
        "last": "Gurwitz D"
      },
      "evidence": "Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, & Benndorf, 2010; McIntyre, Caffe, Michalak, & Reid, 1997).",
      "key": "693ee6c9e3ad85ec81ddc29cc3f458cb",
      "line": 166,
      "relation": "decreases",
      "source": 5,
      "target": 28
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"Angiotensin I\")",
      "concept": {
        "name": "Angiotensin I",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "6af52f2989caaf4daa5adeac24e9215a"
    },
    {
      "bel": "a(CHEBI:\"angiotensin II\")",
      "concept": {
        "name": "angiotensin II",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "17c2386466aa664335d7eeca2063bf1f"
    },
    {
      "bel": "a(CHEBI:\"angiotensin receptor antagonist\")",
      "concept": {
        "name": "angiotensin receptor antagonist",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "804e9c51456ff53ac97de8fdb426e46e"
    },
    {
      "bel": "a(CHEBI:losartan)",
      "concept": {
        "name": "losartan",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "75acc65a998a7c84833f9eaafc14afa2"
    },
    {
      "bel": "a(CHEBI:olmesartan)",
      "concept": {
        "name": "olmesartan",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "65ccf4493ab1b65a6dcce03d8561c46c"
    },
    {
      "bel": "a(CHEBI:telmisartan)",
      "concept": {
        "name": "telmisartan",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8650eac6c506585be1b32c712914612d"
    },
    {
      "bel": "a(PUBCHEM:123805)",
      "concept": {
        "name": "123805",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "4aa07102afa0846ec733e1c879ba25e9"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
      "concept": {
        "name": "Severe acute respiratory syndrome coronavirus 2",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "c41851da59cc36c21b2e8acf24c1f46d"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome-related coronavirus\")",
      "concept": {
        "name": "Severe acute respiratory syndrome-related coronavirus",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "a824ba056422b4e42996cd3269ec9a19"
    },
    {
      "bel": "bp(GO:\"lung epithelium development\")",
      "concept": {
        "name": "lung epithelium development",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "4ff405119d1cb739534c8ad786f37776"
    },
    {
      "bel": "bp(GO:vasoconstriction)",
      "concept": {
        "name": "vasoconstriction",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "407b9c02f282c6a2ac0ba14924d4ebd7"
    },
    {
      "bel": "bp(GO:vasodilation)",
      "concept": {
        "name": "vasodilation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "78248e73a727a8768d39a69d4b3447a9"
    },
    {
      "bel": "bp(MESH:\"Blood Pressure\")",
      "concept": {
        "name": "Blood Pressure",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "fe4965bd3798a9aa6b28451e5d343b76"
    },
    {
      "bel": "bp(MESH:\"Renin-Angiotensin System\")",
      "concept": {
        "name": "Renin-Angiotensin System",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "f80fbf58ffc396be8b673c9ad4850284"
    },
    {
      "bel": "complex(a(CHEBI:\"angiotensin II\"), p(HGNC:AGTR1))",
      "function": "Complex",
      "id": "6872471c911c339823785212ff43935f",
      "members": [
        {
          "bel": "a(CHEBI:\"angiotensin II\")",
          "concept": {
            "name": "angiotensin II",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "17c2386466aa664335d7eeca2063bf1f"
        },
        {
          "bel": "p(HGNC:AGTR1)",
          "concept": {
            "name": "AGTR1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "aaf1fa632bd4a29e5095caf17491bb89"
        }
      ]
    },
    {
      "bel": "complex(a(TAX:\"Severe acute respiratory syndrome coronavirus 2\"), p(HGNC:ACE2))",
      "function": "Complex",
      "id": "146428e3b0f07633969567cac441971e",
      "members": [
        {
          "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
          "concept": {
            "name": "Severe acute respiratory syndrome coronavirus 2",
            "namespace": "TAX"
          },
          "function": "Abundance",
          "id": "c41851da59cc36c21b2e8acf24c1f46d"
        },
        {
          "bel": "p(HGNC:ACE2)",
          "concept": {
            "name": "ACE2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
        }
      ]
    },
    {
      "bel": "complex(a(TAX:\"Severe acute respiratory syndrome-related coronavirus\"), p(HGNC:ACE2))",
      "function": "Complex",
      "id": "c4918aaf8ae8229143e4b1dab5df7531",
      "members": [
        {
          "bel": "a(TAX:\"Severe acute respiratory syndrome-related coronavirus\")",
          "concept": {
            "name": "Severe acute respiratory syndrome-related coronavirus",
            "namespace": "TAX"
          },
          "function": "Abundance",
          "id": "a824ba056422b4e42996cd3269ec9a19"
        },
        {
          "bel": "p(HGNC:ACE2)",
          "concept": {
            "name": "ACE2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
        }
      ]
    },
    {
      "bel": "complex(p(COVID:S), p(HGNC:ACE2))",
      "function": "Complex",
      "id": "6b8514d35b9a04dcfdf30d01d4a3a0a0",
      "members": [
        {
          "bel": "p(COVID:S)",
          "concept": {
            "name": "S",
            "namespace": "COVID"
          },
          "function": "Protein",
          "id": "8d090715298e11996081058536798c19"
        },
        {
          "bel": "p(HGNC:ACE2)",
          "concept": {
            "name": "ACE2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:ACE2), p(UNIPROT:P59594))",
      "function": "Complex",
      "id": "5f0fba1d2f3748b26fc96f962647074c",
      "members": [
        {
          "bel": "p(HGNC:ACE2)",
          "concept": {
            "name": "ACE2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
        },
        {
          "bel": "p(UNIPROT:P59594)",
          "concept": {
            "name": "P59594",
            "namespace": "UNIPROT"
          },
          "function": "Protein",
          "id": "7543d9372e2f08df7ae62ef5685b391b"
        }
      ]
    },
    {
      "bel": "p(COVID:S)",
      "concept": {
        "name": "S",
        "namespace": "COVID"
      },
      "function": "Protein",
      "id": "8d090715298e11996081058536798c19"
    },
    {
      "bel": "p(HGNC:ACE)",
      "concept": {
        "name": "ACE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a42fa7a0be4ac760f67482e649ad0441"
    },
    {
      "bel": "p(HGNC:ACE2)",
      "concept": {
        "name": "ACE2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
    },
    {
      "bel": "p(HGNC:AGTR1)",
      "concept": {
        "name": "AGTR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "aaf1fa632bd4a29e5095caf17491bb89"
    },
    {
      "bel": "p(HGNC:MAS1)",
      "concept": {
        "name": "MAS1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f184c92e08b12600504777d4e9709984"
    },
    {
      "bel": "p(RGD:Ace2)",
      "concept": {
        "name": "Ace2",
        "namespace": "RGD"
      },
      "function": "Protein",
      "id": "fc0dd4c233d000bca280022d54814417"
    },
    {
      "bel": "p(RGD:Agtr1a)",
      "concept": {
        "name": "Agtr1a",
        "namespace": "RGD"
      },
      "function": "Protein",
      "id": "f69bfe045ab54d1046e3fe41dc6dde0b"
    },
    {
      "bel": "p(UNIPROT:P59594)",
      "concept": {
        "name": "P59594",
        "namespace": "UNIPROT"
      },
      "function": "Protein",
      "id": "7543d9372e2f08df7ae62ef5685b391b"
    },
    {
      "bel": "path(DO:\"COVID-19\")",
      "concept": {
        "name": "COVID-19",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "6f9f1c2e8012537e503a758c6bfaff0f"
    },
    {
      "bel": "path(DO:\"kidney disease\")",
      "concept": {
        "name": "kidney disease",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "316c0069dadedc0abd86beb4e68899fb"
    },
    {
      "bel": "path(DO:\"severe acute respiratory syndrome\")",
      "concept": {
        "name": "severe acute respiratory syndrome",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "06fc6690e6ddfff254197e953a470c95"
    },
    {
      "bel": "path(DO:hypertension)",
      "concept": {
        "name": "hypertension",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "53d5b8bd814074e87b1da1ff6250dcff"
    },
    {
      "bel": "path(DO:pneumonia)",
      "concept": {
        "name": "pneumonia",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "274776fc664e9bfd9c191cca80623b0d"
    },
    {
      "bel": "path(MESH:\"Lung Injury\")",
      "concept": {
        "name": "Lung Injury",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0331236e5bff96357737ca4f300a8893"
    },
    {
      "bel": "rxn(reactants(a(CHEBI:\"Angiotensin I\")), products(a(CHEBI:\"angiotensin II\")))",
      "function": "Reaction",
      "id": "56a45e6a5eab5f1a2df86c48565300b1",
      "products": [
        {
          "bel": "a(CHEBI:\"angiotensin II\")",
          "concept": {
            "name": "angiotensin II",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "17c2386466aa664335d7eeca2063bf1f"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:\"Angiotensin I\")",
          "concept": {
            "name": "Angiotensin I",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "6af52f2989caaf4daa5adeac24e9215a"
        }
      ]
    }
  ]
}